This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ravn, P. Articles by Christiansen, C. Search for Related Content PubMed PubMed Citation Articles by Ravn, P. Articles by Christiansen, C.

Monitoring of Alendronate Treatment and Prediction of Effect on Bone Mass by Biochemical Markers in the Early Postmenopausal Intervention Cohort Study¹

Center for Clinical and Basic Research (P.R., N.H.B., C.C.), Ballerup 2750, Denmark; Bone and Mineral Unit (D.H.), City Hospital, Nottingham NG5 1PB, United Kingdom; Merck Research Laboratories (D.T., G.C., A.J.Y.), Rahway, New Jersey 07065; Hawaii Osteoporosis Center (R.D.W.), Honolulu, Hawaii 96814; Center for Metabolic Bone Disorder (M.M.), Portland, Oregon 97213

Address all correspondence and requests for reprints to: Pernille Ravn, M.D., Center for Clinical and Basic Research, Ballerup Byvej 222, 2750 Ballerup, Denmark.

To establish whether biochemical markers could be used to monitor alendronate (ALN) treatment and predict long-term response in bone mass, we used results from an ongoing, randomized trial of ALN treatment for prevention of postmenopausal osteoporosis (n = 1202). In women treated with ALN (5 mg), change from baseline at month 6 in urine N-telopeptide cross-links of type I collagen (NTX) and osteocalcin (OC) correlated with change from baseline at month 24 in spine, hip, and total body bone mineral density (BMD) [r = -0.28 to -0.31 (NTX) and r = -0.16 to -0.25 (OC), P < 0.001]. This corresponded to a 4- to 5-fold greater increase at month 24 in BMD in the tertiles, with the greatest decrease at month 6 in NTX or OC. In women treated with ALN (5 mg) who had a change at month 24 in spine BMD of at least 0%, 86% (NTX) and 79% (OC) had a decrease at month 6 of at least 40% (NTX) or 20% (OC) (sensitivity). The corresponding specificities were 48% (NTX) and 53% (OC). In conclusion, change at month 6 in NTX and OC, in groups of women treated with ALN, indicated the numeric long-term response in BMD within these groups. In individual women, a decrease at month 6, in NTX or OC below the cut-point, validly identified women who responded, on ALN treatment, with a stabilization or an increase in bone mass. However, lack of decrease below the cut-point in NTX or OC could not be used to identify women with a bone loss during ALN treatment.

This article has been cited by other articles:

				M. E. Kraenzlin Biochemical Markers of Bone Turnover and Osteoporosis Management IBMS BoneKEy, July 1, 2007; 4(7): 191 - 203. [Abstract] [Full Text] [PDF]

				M. J. Valimaki and R. Tahtela Serum Tartrate-Resistant Acid Phosphatase 5b or Amino-Terminal Propeptide of Type I Procollagen for Monitoring Bisphosphonate Therapy in Postmenopausal Osteoporosis? Clin. Chem., December 1, 2005; 51(12): 2382 - 2385. [Full Text] [PDF]

				S. L. Greenspan, N. M. Resnick, and R. A. Parker Early Changes in Biochemical Markers of Bone Turnover Are Associated with Long-Term Changes in Bone Mineral Density in Elderly Women on Alendronate, Hormone Replacement Therapy, or Combination Therapy: A Three-Year, Double-Blind, Placebo-Controlled, Randomized Clinical Trial J. Clin. Endocrinol. Metab., May 1, 2005; 90(5): 2762 - 2767. [Abstract] [Full Text] [PDF]

				E Dogan and C Posaci Monitoring hormone replacement therapy by biochemical markers of bone metabolism in menopausal women Postgrad. Med. J., December 1, 2002; 78(926): 727 - 731. [Abstract] [Full Text] [PDF]